In persons who have had a heart attack or have severe chest discomfort, ticagrelor is used in combination with aspirin to prevent serious life-threatening issues with the heart and blood vessels. It's also used to keep blood clots from forming in people with a history of heart attack or severe chest pain who have coronary stents. Due to a large patient pool suffering from cardiac diseases, rising generic medication development, and improving market access scenarios, the worldwide ticagrelor market is predicted to increase at a significant rate throughout the forecast period.
The Ticagrelor Market is predicted to grow because of the rising global burden of heart diseases.
Heart disease's rising prevalence has a direct impact on worldwide morbidity and mortality. According to the American Heart Association and American Stroke Association's 2017 data update, cardiovascular illness was the underlying cause of almost 801,000 fatalities in 2017, accounting for roughly one out of every three deaths in the United States. In 2017, 92.1 million American adults were living with some sort of cardiovascular disease or the after-effects of a stroke, according to the same source.
Furthermore, during the projected period, a considerable increase in the number of Ticagrelor Market approvals from the US Food and Drug Administration (USFDA) will aid in the expansion of the ticagrelor market. For example, the USFDA granted approval in July 2018 for Alembic Pharmaceuticals' ticagrelor tablets to reduce the rate of cardiovascular mortality and stroke in patients with the acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
Regional Analysis of the Ticagrelor Market
The global ticagrelor market is segmented into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Because of the increased mergers and acquisitions of important firms, the ticagrelor industry is dominated by North America. For example, PhaseBio Pharmaceuticals, Inc. signed an exclusive, worldwide license deal with MedImmune, AstraZeneca's global biologics research and development arm, in November 2017 for PB2452 (previously MEDI2452), a phase 1-ready ticagrelor reversal agent. Ticagrelor Market binds to platelet receptors in a reversible manner.
Competitive Landscape of the Ticagrelor Market
C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. are some of the major competitors in the ticagrelor industry.
0 Comments